Board meeting on 05th November, 2026 to approve September quarter and half year results
Eiko Lifesciences has scheduled a Board meeting on Thursday, 05th November, 2026.
By ScoutQuest · · 1 min read
- Board Meeting Date
- Thursday, 05th November, 2026
- Results Period
- quarter and half year ended 30th September, 2026
- Trading Window Closure
- closed from 01st October, 2026, till 48 hours after these results are declared
What was announced
- A meeting of the Board of Directors of Eiko Lifesciences is scheduled for Thursday, 05th November, 2026.
- The main agenda is to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September, 2026.
- A second item covers any other matter, with the permission of the chair.
Why this matters
This is the regular quarterly results announcement. The board meets to sign off the numbers for the three months and the six months ended 30th September, 2026, in both standalone and consolidated form. The standalone numbers cover the company on its own; the consolidated numbers include its subsidiaries or group entities. Investors typically read both together to see how the core business is doing and how the group as a whole is doing.
Trading window
- The trading window for dealing in the company's securities is already closed from 01st October, 2026.
- It stays closed for all designated persons and their immediate relatives till 48 hours after the results are declared.
- This is a routine restriction that applies around results so that people with early access to the numbers do not trade on them.
What to look for in the results
- The standalone and consolidated revenue and profit figures for the quarter ended 30th September, 2026.
- How the half year figures compare with the company's own commentary and earlier periods.
- Any notes the board places alongside the results, which can explain movements in the numbers.
Basis of the intimation
The Board meeting intimation has been shared under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the results are to be approved in line with Regulation 33 of the same regulations.
Also from Eiko Lifesciences
Board approves Q2 & H1 FY27 results; 50-50 joint venture with Oval Projects Engineering considered and approved
5 Nov 2026
Eiko Lifesciences Ltd: promoter reports a transaction via preferential allotment
19 Oct 2026
Board approves allotment of 1.5 lakh equity shares on conversion of warrants
16 Oct 2026
More numbers
- Trading window closure after declaration of results48 hours
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.